Campath (alemtuzumab) Disease Interactions
There are 3 disease interactions with Campath (alemtuzumab):
Alemtuzumab (applies to Campath) cytopenias
Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
Severe, including fatal, autoimmune anemia and thrombocytopenia, and prolonged myelosuppression have been reported in patients receiving alemtuzumab. It is recommended to withhold therapy for severe cytopenias and to discontinue therapy for autoimmune cytopenias or recurrent/persistent severe cytopenias (except lymphopenia). It is recommended to monitor complete blood counts (CBC) at weekly intervals during therapy and more frequently if worsening anemia, neutropenia, or thrombocytopenia occurs and to assess CD4+ counts after treatment until recovery to >= 200 cells/µL.
Alemtuzumab (applies to Campath) cardiac/pulmonary disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease, Pulmonary Impairment
The use of alemtuzumab can cause severe infusion reactions, including pyrexia, chills/rigors, nausea, hypotension, urticaria, dyspnea, rash, emesis, and bronchospasm. Caution should be taken in patients with a history of pulmonary disease, heart disease as they may require dose-escalation and additional pre-infusion medications to manage complications as appropriate.
Alemtuzumab (applies to Campath) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Alemtuzumab should be used with caution in patients at risk of opportunistic infections, as therapy could result in severe and prolonged lymphopenia. It is recommended to administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes viral during and for a minimum of 2 months after completion of therapy or until the CD4+ count is >=200 cells/µL. Routinely monitor patients for CMV infection during therapy and withhold therapy for serious infections and during antiviral treatment for CMV infection or confirmed CMV viremia.
Campath (alemtuzumab) drug interactions
There are 387 drug interactions with Campath (alemtuzumab)
More about Campath (alemtuzumab)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- Drug class: CD52 monoclonal antibodies
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.